Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

The results were unexpectedly positive, showing that orally delivered DehydraTECH-tirzepatide reached roughly equal end of Study blood-concentration levels as the injected drug. During the 8-day ...